Saccomano Nicholas A 4
4 · OnKure Therapeutics, Inc. · Filed Mar 24, 2026
Research Summary
AI-generated summary of this filing
OnKure (OKUR) CEO Nicholas A. Saccomano Sells 86 Shares
What Happened
- Nicholas A. Saccomano, President & CEO and Director of OnKure Therapeutics (OKUR), sold 86 shares on 2026-03-23 in an open market/private sale. The weighted-average price reported was $4.16 per share (range $3.995–$4.235), for total proceeds of roughly $357.
- This sale was executed automatically to cover tax withholding obligations associated with the vesting of restricted stock units (RSUs), per the issuer’s 2023 RSU Equity Incentive Plan — a routine, non-discretionary tax-withholding sale rather than a voluntary market-timing sale.
Key Details
- Transaction date: 2026-03-23; filing date: 2026-03-24 (filed timely, next-day).
- Shares sold: 86; weighted-average sale price: $4.16; price range across trades: $3.995–$4.235; proceeds ≈ $357.
- Shares owned after transaction: Not specified in the provided filing excerpt.
- Footnotes: F1 — sale to cover tax withholding on RSU vesting; F2 — multiple trades, weighted-average price reported (detailed per-trade prices available on request); F3 — securities were RSUs (each RSU converts to one share subject to vesting).
- Transaction code: S (sale); context code: F (tax withholding).
Context
- Tax-withholding sales on RSU vesting are common and generally reflect routine administrative action (to satisfy tax obligations) rather than a directional bet by the insider. The amount here is small (~$357) relative to typical insider transaction thresholds.
Insider Transaction Report
Form 4
Saccomano Nicholas A
DirectorPresident and CEO
Transactions
- Sale
Class A Common Stock
[F1][F2][F3]2026-03-23$4.16/sh−86$357→ 7,333 total
Footnotes (3)
- [F1]These shares were automatically sold to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"), pursuant to the terms of the Issuer's 2023 RSU Equity Incentive Plan.
- [F2]This transaction was executed in multiple trades at prices ranging from $3.995 to $4.235. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
- [F3]Certain of these securities are RSUs. Each RSU represents a contingent right to receive one share of Class A Common Stock, subject to the applicable vesting schedule and conditions of each RSU.
Signature
/s/ Rogan Nunn, by power of attorney|2026-03-24